ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Novo Nordisk A/S Sponsored ADR Class B (NVO) Report Updated: Aug 25, 2014 | Print This Page

Novo Nordisk A/S Sponsored ADR Class B© quotemedia

Company Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, obesity, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in approximately 190 countries. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Recent News: Novo Nordisk A/S Sponsored ADR Class B